These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30280589)

  • 1. Molecular modelling studies on cinnoline-based BTK inhibitors using docking and structure-based 3D-QSAR.
    Li R; Du Y; Shen J
    SAR QSAR Environ Res; 2018 Nov; 29(11):847-873. PubMed ID: 30280589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Modeling Studies on Carbazole Carboxamide Based BTK Inhibitors Using Docking and Structure-Based 3D-QSAR.
    Li R; Du Y; Gao Z; Shen J
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29671827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modeling studies on series of Btk inhibitors using docking, structure-based 3D-QSAR and molecular dynamics simulation: a combined approach.
    Balasubramanian PK; Balupuri A; Cho SJ
    Arch Pharm Res; 2016 Mar; 39(3):328-39. PubMed ID: 26699616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor-guided 3D-QSAR studies, molecular dynamics simulation and free energy calculations of Btk kinase inhibitors.
    Balasubramanian PK; Balupuri A; Kang HY; Cho SJ
    BMC Syst Biol; 2017 Mar; 11(Suppl 2):6. PubMed ID: 28361711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atom and receptor based 3D QSAR models for generating new conformations from pyrazolopyrimidine as IL-2 inducible tyrosine kinase inhibitors.
    Ul-Haq Z; Effendi JS; Ashraf S; Bkhaitan MM
    J Mol Graph Model; 2017 Jun; 74():379-395. PubMed ID: 28499271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
    Zeng H; Zhang H
    J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Gozzetti A; Candi V; Brambilla CZ; Papini G; Fabbri A; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(8):1040-1045. PubMed ID: 27697038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors.
    Zou Y; Xiao J; Tu Z; Zhang Y; Yao K; Luo M; Ding K; Zhang Y; Lai Y
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3052-3059. PubMed ID: 27210433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative structure-activity relationship study on BTK inhibitors by modified multivariate adaptive regression spline and CoMSIA methods.
    Xu A; Zhang Y; Ran T; Liu H; Lu S; Xu J; Xiong X; Jiang Y; Lu T; Chen Y
    SAR QSAR Environ Res; 2015; 26(4):279-300. PubMed ID: 25906044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D-QSAR CoMFA and CoMSIA study on benzodipyrazoles as cyclin dependent kinase 2 inhibitors.
    Dessalew N; Singh SK
    Med Chem; 2008 Jul; 4(4):313-21. PubMed ID: 18673142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
    Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
    Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2D and 3D-QSAR analysis of pyrazole-thiazolinone derivatives as EGFR kinase inhibitors by CoMFA and CoMSIA.
    Pourbasheer E; Aalizadeh R; Shiri HM; Banaei A; Ganjali MR
    Curr Comput Aided Drug Des; 2015; 11(4):292-303. PubMed ID: 26548551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bruton's TK inhibitors: structural insights and evolution of clinical candidates.
    Xing L; Huang A
    Future Med Chem; 2014 Apr; 6(6):675-95. PubMed ID: 24895895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
    Bavi R; Kumar R; Choi L; Woo Lee K
    PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D-QSAR and molecular docking study of LRRK2 kinase inhibitors by CoMFA and CoMSIA methods.
    Pourbasheer E; Aalizadeh R
    SAR QSAR Environ Res; 2016 May; 27(5):385-407. PubMed ID: 27228480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QSAR analysis of nicotinamidic compounds and design of potential Bruton's tyrosine kinase (Btk) inhibitors.
    Santos-Garcia L; Assis LC; Silva DR; Ramalho TC; da Cunha EF
    J Biomol Struct Dyn; 2016 Jul; 34(7):1421-40. PubMed ID: 26305710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D-QSAR, molecular dynamics simulations, and molecular docking studies on pyridoaminotropanes and tetrahydroquinazoline as mTOR inhibitors.
    Chaube U; Bhatt H
    Mol Divers; 2017 Aug; 21(3):741-759. PubMed ID: 28577112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.
    Liu L; Shi B; Wang X; Xiang H
    Future Med Chem; 2018 Feb; 10(3):343-356. PubMed ID: 29347836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation.
    He Q; Han C; Li G; Guo H; Wang Y; Hu Y; Lin Z; Wang Y
    Comput Biol Chem; 2020 Oct; 88():107328. PubMed ID: 32688011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.